Equities

Sprint Bioscience AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Sprint Bioscience AB

Actions
  • Price (SEK)1.85
  • Today's Change0.150 / 8.82%
  • Shares traded1.82m
  • 1 Year change+21.06%
  • Beta0.1701
Data delayed at least 15 minutes, as of Feb 09 2026 17:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.

  • Revenue in SEK (TTM)49.53m
  • Net income in SEK-25.65m
  • Incorporated2009
  • Employees29.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Abera Bioscience AB0.00-1.45m118.30m5.00--4.21-----0.0872-0.08720.001.510.00----0.00-6.61-68.96-7.94-85.65------------0.00------93.42------
Alzinova AB205.00k-26.88m118.34m5.00--0.5785--577.29-0.2846-0.28460.00221.230.0015--0.325441,000.00-19.42-12.21-20.69-12.85-5,834.15---13,114.15-21,390.81---1,794.800.0062---88.89---24.71--19.48--
Biovica International AB9.86m-76.47m122.23m24.00--1.05--12.39-0.6375-0.63750.06840.42410.079912.714.46365,333.30-61.92-58.22-70.41-66.49-171.53-462.09-775.22-1,804.168.11--0.0239--18.2338.8329.80---47.26--
SoftOx Solutions AS12.65m-2.79m136.06m5.00--1.35181.4410.75-0.001-0.0010.00650.04450.123--30.132,717,798.00-2.72-50.91-3.22-67.07-----22.07-644.921.16-3.920.1212--13.3814.06-8.86------
ViroGates A/S7.20m-17.68m161.66m7.00--33.28--22.46-1.63-1.630.66090.36650.35680.97774.41504,300.00-87.63-54.92-131.36-63.1547.3372.98-245.63-215.481.58-16.130.6277---12.276.45-18.59------
SenzaGen AB57.88m-16.18m164.04m37.00--2.21--2.83-0.5483-0.54831.962.520.55775.476.631,702,294.00-15.59-20.91-18.89-25.1765.0967.10-27.95-71.432.73--0.0707--15.6984.1619.22---1.18--
NextCell Pharma AB10.94m-35.14m176.89m24.00--2.66--16.17-0.4414-0.44140.1330.5960.138451.234.68---44.48-34.95-49.25-37.53-155.37-266.34-321.31-427.089.92------2.5625.1316.25--36.88--
Sprint Bioscience AB49.53m-25.65m179.38m29.00--29.58--3.62-0.2986-0.29860.58320.05751.47--6.021,303,316.00-76.04-60.40-262.43-100.7261.9457.87-51.79-87.25---36.010.00--30.0214.37-4,072.83--69.39--
Oncoinvent ASA5.03m-100.17m179.46m7.00--0.3918--35.66-176.33-176.338.86109.850.0354--0.4134360,333.30-70.49-68.76-88.81-82.93-----1,990.44-40,397.77----0.00--139.55-37.5126.85------
Initiator Pharma A/S0.00-16.55m196.01m2.00--4.24-----0.2748-0.27480.000.67570.00----0.00-43.00-67.58-46.15-73.43------------0.0619------53.32------
Circio Holding ASA0.00-8.56m196.16m9.008.07------0.13480.13480.00-0.08360.00----0.00-93.87-47.84---58.78-------6,460.26---------100.00--150.93--7.12--
Xbrane Biopharma AB209.08m-72.86m209.97m26.00--0.3577--1.00-5.168.9914.5728.490.27130.28995.003,216,539.00-9.46-37.48-15.30-65.1371.25---34.85-233.691.71-1.490.00---16.76--17.70--113.17--
Dextech Medical AB0.00-4.96m210.74m1.00--8.81-----0.2684-0.26840.001.290.00----0.00-18.58-19.36-18.94-19.80------------0.00-------2.96--40.14--
AlzeCure Pharma AB0.00-39.20m214.32m11.00--4.23-----0.4047-0.40470.000.44090.00----0.00-71.83-73.70-88.08-83.65------------0.053------5.20---38.94--
Xintela AB2.96m-42.28m234.26m13.00------79.22-0.0665-0.06650.0046-0.03960.3486--6.47227,461.50-498.42-194.17---651.77100.00---1,429.86-6,272.93---16.40----5,303.85156.4527.54------
Klaria Pharma Holding AB (publ)11.23m-58.70m243.02m4.00--53.47--21.63-0.4069-0.30930.06990.01850.201--5.342,808,250.00-105.02-48.20-649.38-74.06-----522.58-1,522.52---2.470.1195---73.41-11.85-33.44------
Data as of Feb 09 2026. Currency figures normalised to Sprint Bioscience AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.